期刊文献+

体检人员常见肿瘤标志物异常的临床意义 被引量:5

Clinical Significance of Tumor Marker Elevation in Screened Person
原文传递
导出
摘要 [目的]探讨体检发现肿瘤标志物异常对诊断肿瘤的临床意义。[方法]129例常规体检发现的肿瘤标志物(CEA、CA199、CA724、CA125、CA242、SCC、NSE、CYFRA211)升高人员,对其进行颈胸部、腹盆部CT、内窥镜检查,女性进行妇科检查,未明确诊断者进行长期随访(大于6个月)。[结果]经过随访,共发现肿瘤患者22例,其中发现肿瘤标志物升高6个月内诊断为恶性肿瘤15例(68.2%),6个月至1年诊断3例(13.9%),1年至2年诊断2例(9.1%),2年至3年诊断2例(9.1%)。COX分析显示肿瘤标志物升高的程度(RR=1.154,95%CI:1.078~1.237,P〈0.001)、肿瘤标志物逐渐升高(RR=3.863,95%CI:1.504~9.919,P〈0.005)和有相关临床症状(RR=3.935,95%CI:1.178~13.14,P〈0.05)是体检肿瘤标志物升高人员患肿瘤的危险因素。[结论]对于体检发现的肿瘤标志物升高人员,应进行全面的临床检查并进行长期随访。 [Purpose] To investigate the clinical significance of tumor marker elevation during physical examination in diagnosis for tumor. [Methods] One hundred and twenty-nine screened person with elevated tumor marker(CEA,CA199,CA724,CA125,CA242,SCC,NSE,CYFRA211) were collected. Cervical,thorax,abdominal and pelvic CT,gastric endoscopy and colonoscopy were carried out for them. TCT and HPV were also performed for female. Uncerating persons were followed up for a long term(more than 6 months).[Results] After follow up,there were 22 cancer patients was found. Among them,15 cases(68.2%) were diagnosed within 6 months from the elevation of tumor markers, 3 cases(13.9%) within one year,2 cases(9.1%) within two years,and 2 cases(9.1%) within three years. COX analysis showed that degree elevated tumor markers(RR=1.154,95%CI:1.078~1.237,P 0.001),tumor markers increased gradually(RR=3.863,95%CI:1.504~9.919,P0.005) and relevant symptoms(RR=3.935,95%CI:1.178~13.14,P0.05) were the cancer risk factors of screened person. [Conclusions] Systemic clinical examination and long-term follow up should be carried out for person with elevated tumor marker.
机构地区 中国医学科学院
出处 《中国肿瘤》 CAS 2013年第12期1029-1032,共4页 China Cancer
基金 北京希望马拉松专项基金(N2009YF51)
关键词 恶性肿瘤 早期诊断 肿瘤标志物 体检 cancer early detection tumor marker elevation physical examination
  • 相关文献

参考文献8

  • 1陈万青,张思维,郑荣寿,雷正龙,李光琳,邹小农,赵平.中国肿瘤登记地区2007年肿瘤发病和死亡分析[J].中国肿瘤,2011,20(3):162-169. 被引量:329
  • 2Kodama I, Koufuji K,Kawabata S,et al. The clinical effi- cacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA [J]. Int Surg, 1995,80 (1) :45-48.
  • 3Bangma CH,Blijenberg BG,Schroder FH. Prostate-specific antigen:its clinical use and application in screening for prostate cancer [J]. Scand J Clin Lab Invest Suppl, 1995,221 : 35-44.
  • 4Bast RC Jr,Xu FJ,Yu YH,et al. CA 125:the past and the future[J]. Int J Biol Markers, 1998,13(4): 179-187.
  • 5Wichmann MW,Lau-Werner U,Mfiller C,et al. Carci- noembryonic antigen for the detection of recurrent disease following curative' resection of colorectal cancer [J]. Anti- cancer Res, 2000,20(6D) : 4953-4955.
  • 6Jeyarajah AR, Ind TE, MacDonald N,et al. Increased mor- tality in postmenopausal women with serum CA125 eleva- tion[J]. Gynecol Oncol, 1999,73(2) : 242-246.
  • 7Flanagan FL,Dehdashti F,Ogunbiyi OA. Utility of FDG- PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer [J]. Ann Surg, 1998,227 (3):319-323.
  • 8Ramsey SD,Yoon P,Moonesinghe R,et al. Population- based study of the prevalence of family history of cancer: Implications for cancer screening and prevention[J]. Genet Med, 2006,8(9) : 571-575.

二级参考文献10

  • 1Bray F, Parkin DM, Evaluation of data quality in the cancer registry: Principles and methods. Part I : Comparability, validity and timeliness [J]. Eur J Cancer, 2009, 45(5): 747-755.
  • 2Curado MP, Edwards B, Shin HR et al. Cancer incidence in five conti- nents, Vol. IX. IARC scientific publications No. 160[M]. Lyon: IARC, 2007.
  • 3Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IAtlC technical report No.19[M]. Lyon: IARC. 1994.
  • 4Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005.
  • 5Felay J. The IARCcrgTools program [CP/OL]. http://www.iaer.com.fr/iarc- crgtools.htm, 2006.
  • 6全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 7陈万青,张思维.中国肿瘤登记的代表性研究[J].中国肿瘤,2008,17(10):832-835. 被引量:12
  • 8陈万青,赵平,饶克勤,孔灵芝,胡建平.健全我国肿瘤登记系统[J].中华预防医学杂志,2010,44(5):374-375. 被引量:12
  • 9张思维,雷正龙,李光琳,邹小农,赵平,陈万青.中国肿瘤登记地区2006年肿瘤发病和死亡资料分析[J].中国肿瘤,2010,19(6):356-365. 被引量:193
  • 10陈建国.癌症登记资料的质量评价[J].中国肿瘤,1999,8(3):100-104. 被引量:39

共引文献328

同被引文献39

引证文献5

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部